As healthcare professionals, our understanding of Parkinson's disease (PD) is crucial in providing effective patient care. PD is a progressive, neurodegenerative disorder that affects movement, muscle control, and balance.
PD primarily affects the dopamine-producing neurons in the substantia nigra, a region of the brain that controls movement. The exact cause is unknown, but both genetic and environmental factors are implicated. The characteristic motor symptoms are due to the loss of dopamine, resulting in an imbalance of excitatory and inhibitory signals in the basal ganglia.
PD typically presents with resting tremor, bradykinesia, rigidity, and postural instability. However, non-motor symptoms such as depression, cognitive impairment, and autonomic dysfunction often precede the motor symptoms and significantly affect the quality of life.
PD is primarily diagnosed clinically, based on the presence of cardinal motor symptoms and their response to dopaminergic therapy. Neuroimaging and genetic testing can support the diagnosis but are not routinely used due to their limited sensitivity and specificity.
While there is no cure for PD, the goal of treatment is to manage symptoms and improve quality of life. Pharmacological therapy, primarily with levodopa and dopamine agonists, is the mainstay of treatment. Non-pharmacological interventions, including physical therapy and lifestyle modifications, also play a crucial role.
Understanding Parkinson's disease is paramount for healthcare professionals. By recognizing the clinical features, understanding the pathophysiology, and being aware of the latest treatment strategies, we can ensure that our patients receive the best possible care. Continuous research and advancements in this field offer hope for better management strategies and, ultimately, a cure for this debilitating disease.
1.
Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.
2.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
3.
New imaging guidelines for head and neck cancers, a step toward practice change
4.
How wildfires pose challenges to cancer care
5.
Annual whole-body, low-dose CT aids management of smoldering multiple myeloma
1.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
2.
Mitoxantrone–Napabucasin Co-Nanoformulation Activates cGAS-STING in HCC Therapy
3.
Geriatric Medicine Through Long-Term Functional Survivorship After Cancer in Older Adults
4.
Omentum Cancer: Causes, Symptoms, and Treatment Options
5.
Advanced Directions in Oncology and Quality Improvement
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
When Unexplained Bruising May Require Blood Testing
2.
Current Scenario of Cancer- The Incidence of Cancer in Men
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation